Citigroup Initiates Coverage On Zenas BioPharma with Buy Rating, Announces Price Target of $27
Portfolio Pulse from Benzinga Newsdesk
Citigroup has initiated coverage on Zenas BioPharma with a Buy rating and set a price target of $27.

October 08, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has initiated coverage on Zenas BioPharma with a Buy rating and a price target of $27, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a major financial institution like Citigroup is likely to positively influence investor sentiment and could lead to an increase in ZBIO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100